|
| Press Releases |
|
 |
|
| Monday, May 5, 2025 |
|
|
Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards |
| Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech's new Gene Therapy Center with dedicated cGMP facilities for virus-related projects. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
Micreos Pharmaceuticals 與生物製劑 CDMO Northway Biotech 合作推動其工程化內溶素療法製造計畫 |
| more info >> |
|
|
Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program |
| Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis. more info >> |
|
| Wednesday, February 5, 2025 |
|
|
Mallia Therapeutics 與 Northway Biotech 宣布合作生產可溶性 CD83 蛋白 用於脫髮治療 |
| Mallia Therapeutics（「Mallia」）是一家致力於開發新型脫髮治療方案的生物製藥公司，Northway Biotech（「NBT」）則是一家專業從事生物製劑的合同開發與製造組織（CDMO）。雙方宣布建立合作夥伴關係，共同開發 Mallia 的可溶性 CD83 蛋白（sCD83）生產工藝，並負責其製造，該治療方案旨在促進毛囊形成與生長。 more info >> |
|
| Tuesday, February 4, 2025 |
|
|
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment |
| Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth. more info >> |
|
| Tuesday, August 1, 2023 |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
| Thursday, May 25, 2023 |
|
|
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts |
| Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape. more info >> |
|
| Wednesday, May 17, 2023 |
|
|
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat |
| tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
從項目攻堅到生態賦能：一文看懂五菱汽車無人駕駛的進化密碼
May 30, 2025 21:31 HKT/SGT
|
|
|
Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind
May 30, 2025 19:00: JST
|
|
|
Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind
May 30, 2025 19:00 HKT/SGT
|
|
|
Mitsubishi Corporation Establishes New Corporate Venture Capital Company
May 30, 2025 18:36 JST
|
|
|
トヨタ・モビリティ基金「タテシナ会議」自転車・二輪分科会、群馬県と連携し高校生の自転車事故半減に向けた啓発活動を開始
May 30, 2025 14:00: JST
|
|
|
富士通の特例子会社が田島支援学校併設のベーカリーカフェをオープン
May 30, 2025 14:00: JST
|
|
|
The PropertyGuru Asia Property Awards (Middle East) return for 2025 edition with inaugural Dubai launch
May 30, 2025 14:00 HKT/SGT
|
|
|
Honda to Co-develop Refueling Port Connecting System for On-orbit Satellite Refueling with Astroscale
May 30, 2025 11:54 JST
|
|
|
IFS and NEC Strengthen their Strategic Partnership to Create New Value
May 30, 2025 10:11 JST
|
|
|
Genetec maintains profitability in Q3FY2025 on higher revenue
May 29, 2025 20:00 HKT/SGT
|
|
|
Naoris Protocol Raises $3M in Strategic Round Led by Mason Labs
May 29, 2025 19:00 HKT/SGT
|
|
|
MODONG Coffee Proudly Sponsors "G-DRAGON 2025 WORLD TOUR [Ubermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" as Official Sponsor
May 29, 2025 18:19 HKT/SGT
|
|
|
Mazda Production and Sales Results for April 2025
May 29, 2025 18:44 JST
|
|
|
Euro Manganese Closes C$11.2 million (A$12.3 million) Financing
May 29, 2025 16:09 HKT/SGT
|
|
|
First patient dosed in YK012 trial-the world's first TCE therapy for primary membranous nephropathy
May 29, 2025 15:49 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
